Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily. SAN DIEGO, CA, USA I January 8, 2025 I Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), ...

Medspas are leading the charge in offering GLP-1 treatments, with 60% of medspas in the U.S. now providing these services, compared to 35% of aesthetic physician offices. Average spend per patient ...

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation.

“Alright, I have a confession to make. Yes, I am on a GLP-1 for a weight-loss medication,” Van Ness said.

Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...